SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Status
RECRUITING
Phase
Age
≥ 18 Years
Enrollments
60Conditions
Metastatic Castration-Resistant Prostate CarcinomaSummary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- James Pool
- 734-615-7391
- [email protected]
Principal Investigator
- Yuni K Dewaraja
Eligibility Criteria
Inclusion Criteria:
* * 177Lu-617 PSMA treatment scheduled for mCRPC
* Clinically stable as determined by the nuclear medicine clinicians
* Male
* ≥ 18 years of age
* Willing and able to provide informed consent
Exclusion Criteria:
* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Study Plan
Observational
Patients receive standard care Pluvicto and undergo Lu-177 SPECT/CT scans on study. Patients may also undergo optional 99mTc-SC SPECT/CT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.
OTHER:
Non-Interventional StudyDescription:
Non-interventional study
Outcome Measures
Primary Outcome Measures
Response and toxicity following 177Lu-RLT
Secondary Outcome Measures
Build and test models
Timeline
Last Updated
July 31, 2025Start Date
July 31, 2025Today
October 17, 2025Completion Date ( Estimated )
January 23, 2031
Sponsors of this trial
Lead Sponsor
University of Michigan Rogel Cancer CenterCollaborating Sponsors
National Cancer Institute (NCI)
RECRUITING 
≥ 18 Years